Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Medullary Thyroid Cancer; Bronchial Carcinoid; Gastroenteropancreatic Neuroendocrine Neoplasm
Interventions: Drug: 1 MBq/k of 211At-MABG Fractionated; Drug: 2 MBq/k1 of 211At-MABG Fractionated; Drug: 4 MBq/k of 211At-MABG Fractionated
Sponsors: University of Pennsylvania; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet **RECRUITING NOW**
Interventions: Drug: 1 MBq/k of 211At-MABG Fractionated; Drug: 2 MBq/k1 of 211At-MABG Fractionated; Drug: 4 MBq/k of 211At-MABG Fractionated
Sponsors: University of Pennsylvania; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
